Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of Sacituzumab Tirumotecan in advanced thymic epithelial tumors (second-line and beyond)
ChiCTR2600122047Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in thymic malignancies (TET), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on ChiCTR2600122047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122047.